WFM
DGX icon

Wilmington Funds Management’s Quest Diagnostics DGX Stock Holding History

Wilmington Funds Management’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-4,750
Closed -$275K – 764
2014
Q1 		$275K Hold
4,750
– – 0.03% 551
2013
Q4 		$254K Hold
4,750
– – 0.03% 612
2013
Q3 		$294K Buy
+4,750
New +$284K 0.03% 568

Other funds holding DGX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
DSA
Davis Selected Advisers Tucson, Arizona $21.8B AUM 23.45% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wilmington Funds Management's DGX Position: Q2 2014 in Review

Wilmington Funds Management sold out of Quest Diagnostics (DGX) in Q2 2014, closing a stake of 4,750 shares — an estimated $275K sold.

Wilmington Funds Management first reported a position in DGX in Q3 2013 and held it in 3 quarters. The position peaked at $294K in Q3 2013. 496 funds tracked by Wall St. Rank hold DGX as of Q2 2014.

  • Wilmington Funds Management reported no remaining Quest Diagnostics position as of Q2 2014 after selling out during the quarter.
  • Wilmington Funds Management sold 4,750 Quest Diagnostics shares in Q2 2014, an estimated $275K.
  • Wilmington Funds Management first reported a position in Quest Diagnostics in Q3 2013 and held it in 3 quarters.
  • Wilmington Funds Management's Quest Diagnostics position peaked at $294K in Q3 2013.
  • 496 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2014.

Based on Wilmington Funds Management's 13F filing for Q2 2014, filed 13 Aug 2014.